<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="intensive-chemo-asct-hr-dlbcl-yan">
    <meta name="study:title" content="PB3322 - Efficacy and safety of sequential intensive chemotherapy and autologous hematopoietic stem cell transplantation in the treatment of high-intermediate- or high-risk diffuse large B-cell lymphoma">
    <meta name="study:fileName" content="Abstracts/INTENSIVE-CHEMO-ASCT-HR-DLBCL-YAN.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Rituximab,Monoclonal Antibody,Chemotherapy,CIT,R-HyperCVAD,R-DICE"> <title>PB3322: Intensive Chemo + ASCT in High-Risk DLBCL (Yan) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3322 - Intensive Chemo & ASCT in High-Intermediate/High-Risk DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=19)</h4>
                    <p>High-intermediate/High-risk DLBCL (IPI ≥2). Aim: Eval efficacy/safety of intensive chemo + ASCT.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (2 Groups)</h4>
                    <p>Transplant (N=12): R-HyperCVAD x2 → R-DICE x3 → ASCT. Chemo (N=7): R-HyperCVAD x2 → R-DICE x3 → R-DICE x1.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (CR after C4)</h4>
                    <p>Transplant GRP: <span class="highlight-value">100%</span><br>Chemo GRP: <span class="highlight-value">57.1%</span><br>2-yr OS/PFS (Transplant): 100%/100%</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Hematologic toxicity prominent (G3/4 Neutropenia, Thrombocytopenia). ASCT may benefit survival.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PB3322 - Efficacy and safety of sequential intensive chemotherapy and autologous hematopoietic stem cell transplantation in the treatment of high-intermediate- or high-risk diffuse large B-cell lymphoma</h1>
            <p class="abstract-sub-header">BeiBei Gao, XinNan Chen, YaNan Huang, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PB3322 | Publication Only</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>High-risk DLBCL has high malignancy, strong proliferation, often with complex molecular features (double/triple-hit).</li>
                        <li>ASCT after intensive chemotherapy can prolong survival and reduce recurrence in high-risk patients.</li>
                        <li>Lack of large-scale, high-quality clinical data on long-term efficacy/safety of this approach.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To evaluate the efficacy and safety of sequential intensive chemotherapy and ASCT in high-intermediate- or high-risk DLBCL patients.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <p class="text-sm mb-2">Prospective, open, multicenter, single-arm clinical study.</p>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Primary Endpoint: 2-year PFS.</li>
                        <li>Secondary Endpoints: 2-year OS, CR rate after induction.</li>
                        <li>Patients (N=19) divided into Transplant group (N=12) and Chemotherapy group (N=7).</li>
                    </ul>
                    <div class="study-design-schema">
                        <h3 class="schema-title">Study Design Overview (Figure 1 from Abstract)</h3>
                        <div class="schema-enrollment">
                            <strong>Eligible Patients</strong>
                            <span>18-70 years old</span>
                            <span>Newly diagnosed DLBCL</span>
                            <span>IPI ≥2 (High-Intermediate/High-Risk)</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase">
                                <strong>Induction Therapy (2 cycles)</strong>
                                <span>R-HyperCVAD</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                             <div class="schema-phase">
                                <strong>Consolidation Therapy (3 cycles)</strong>
                                <span>R-DICE</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 48%; background-color: var(--sobi-light-teal-bg);">
                                <strong>Transplant Group (N=12)</strong>
                                <span>ASCT</span>
                            </div>
                            <div style="writing-mode: vertical-rl; text-orientation: mixed; margin: auto 5px; font-weight:bold;">OR</div>
                            <div class="schema-phase" style="flex-basis: 48%; background-color: var(--sobi-light-orange-bg);">
                                <strong>Chemotherapy Group (N=7)</strong>
                                <span>R-DICE (1 cycle)</span>
                            </div>
                        </div>
                         <div class="schema-assessment-points">
                           <span>Response after C2 Chemo</span>
                           <span>Response after C4 Chemo (pre-transplant for ASCT group)</span>
                           <span>2-year PFS & OS</span>
                           <span>Safety</span>
                        </div>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=19)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Transplant Group (n=12)</th><th>Chemotherapy Group (n=7)</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Median Age, years</td><td>60</td><td>56</td></tr>
                                <tr><td>Male, n (%)</td><td>8 (66.7%)</td><td>4 (57.1%)</td></tr>
                                <tr><td>Female, n (%)</td><td>4 (33.3%)</td><td>3 (42.9%)</td></tr>
                                <tr><td>Ann Arbor Stage III-IV, n (%)</td><td>9 (75.0%)</td><td>7 (100.0%)</td></tr>
                                <tr><td>ECOG Score 0, n (%)</td><td>2 (16.7%)</td><td>0</td></tr>
                                <tr><td>ECOG Score 1, n (%)</td><td>8 (66.7%)</td><td>4 (57.1%)</td></tr>
                                <tr><td>ECOG Score 2, n (%)</td><td>0</td><td>3 (42.9%)</td></tr>
                                <tr><td>ECOG Score 3, n (%)</td><td>2 (16.7%)</td><td>0</td></tr>
                                <tr><td>IPI 0-1, n (%)</td><td>4 (33.3%)</td><td>0</td></tr>
                                <tr><td>IPI 2, n (%)</td><td>3 (25.0%)</td><td>2 (28.6%)</td></tr>
                                <tr><td>IPI 3, n (%)</td><td>3 (25.0%)</td><td>4 (57.1%)</td></tr>
                                <tr><td>IPI 4-5, n (%)</td><td>2 (16.6%)</td><td>1 (14.3%)</td></tr>
                                <tr><td>B Symptoms, n (%)</td><td>1 (8.3%)</td><td>3 (42.9%)</td></tr>
                                <tr><td>Double-hit/Double-expression, n (%)</td><td>6 (50.0%)</td><td>2 (28.6%)</td></tr>
                            </tbody>
                        </table>
                        <p class="footnote-text mt-1">Adapted from Table 1 in abstract. Note: Abstract states IPI≥2 for inclusion, but Table 1 shows IPI 0-1 for some transplant patients.</p>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (Median F/U: 17.4 months)</h2>
                    <p class="text-sm mb-2"><strong>Response after 2nd Cycle Chemo:</strong></p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>Transplant Group (N=12): CR 8.3% (1 Pt), PR 83.3% (10 Pts), SD 8.3% (1 Pt)</li>
                        <li>Chemotherapy Group (N=7): PR 100% (7 Pts)</li>
                    </ul>
                     <p class="text-sm mb-2"><strong>Response after 4th Cycle Chemo (pre-transplant for ASCT group):</strong></p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>Transplant Group (N=12): CR 100% (all Pts achieved CR before ASCT; 2 Pts achieved CR after 3 cycles R-DICE)</li>
                        <li>Chemotherapy Group (N=7): CR 57.1% (4 Pts), PR 28.6% (2 Pts), PD 14.3% (1 Pt)</li>
                    </ul>
                     <p class="text-sm mb-2"><strong>Survival Outcomes:</strong></p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>Median OS: Not reached in either group.</li>
                        <li>2-year OS: Transplant Group 100% vs. Chemotherapy Group 68.6%</li>
                        <li>2-year PFS: Transplant Group 100% vs. Chemotherapy Group 80%</li>
                    </ul>
                    <div class="chart-container mb-3">
                        <svg id="intensiveChemoResponseChart" width="400" height="300"></svg>
                        <div id="intensiveChemoResponseLegend" class="legend"></div>
                    </div>
                    <div class="grid grid-cols-1 md:grid-cols-2 gap-4 mt-4">
                        <div class="km-plot-container zoomable-image-container">
                            <img src="https://storage.googleapis.com/generativeai-downloads/ESH2025/PB3322_OS_KM.png" alt="Overall Survival Kaplan-Meier Curve" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/400x300/E0F2F7/0A2F5C?text=OS+Curve+Not+Available';">
                            <p class="text-xs text-center mt-1">Overall Survival (Adapted from Abstract Figure)</p>
                        </div>
                        <div class="km-plot-container zoomable-image-container">
                             <img src="https://storage.googleapis.com/generativeai-downloads/ESH2025/PB3322_PFS_KM.png" alt="Progression-Free Survival Kaplan-Meier Curve" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/400x300/FFF0E5/0A2F5C?text=PFS+Curve+Not+Available';">
                            <p class="text-xs text-center mt-1">Progression-Free Survival (Adapted from Abstract Figure)</p>
                        </div>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary (N=19, 90 total chemo cycles)</h2>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Hematological toxicity was prominent.</li>
                        <li>Grade 3-4 Neutropenia: Occurred in 47/90 cycles.</li>
                        <li>Grade 3-4 Thrombocytopenia: Occurred in 27/90 cycles.</li>
                        <li>Grade 3 Infection: Occurred in 11/90 cycles.</li>
                        <li>No infection-related deaths during chemotherapy or transplantation.</li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>CR rate after 4th cycle was significantly higher in the transplantation group vs. chemotherapy group (100% vs. 57.1%).</li>
                <li>2-year OS and PFS were 100% vs. 68.6% and 100% vs. 80% for transplant vs. chemotherapy groups, respectively.</li>
                <li>Results suggest that transplantation treatment may benefit the survival of patients with high-intermediate/high-risk DLBCL.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <p>ASCT, Autologous Hematopoietic Stem Cell Transplantation; CR, Complete Remission; DLBCL, Diffuse Large B-Cell Lymphoma; ECOG, Eastern Cooperative Oncology Group; F/U, Follow-up; G, Grade; IPI, International Prognostic Index; NHL, Non-Hodgkin Lymphoma; OS, Overall Survival; PD, Progressive Disease; PFS, Progression-Free Survival; PR, Partial Remission; Pt(s), Patient(s); R-DICE, Rituximab, Ifosfamide, Carboplatin, Etoposide; R-HyperCVAD, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin (Adriamycin), Dexamethasone; SD, Stable Disease.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
                Gao B, Chen X, Huang Y, et al. Efficacy and safety of sequential intensive chemotherapy and autologous hematopoietic stem cell transplantation in the treatment of high-intermediate- or high-risk diffuse large B-cell lymphoma. Abstract #PB3322 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PB3322 | Abstract Release: 05/14/2025 | Presentation: 06/12/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script defer src="abstract_features.js"></script>
    <script>
        function drawGroupedBarChartPB3322(containerId, legendContainerId) {
            const chartTitle = "CR Rates after 4 Cycles of Chemotherapy";
            const chartData = [
                { group: "Transplant Group (N=12)", values: { CR: 100, PR: 0, Other: 0 } }, // All CR
                { group: "Chemo Group (N=7)", values: { CR: 57.1, PR: 28.6, Other: 14.3 } } // CR, PR, PD
            ];

            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);

            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 400;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.9, 300);
            }
            
            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");

            const margin = { top: 50, right: 20, bottom: 50, left: 60 };
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <=0) return;

            const g = svg.append("g")
                .attr("transform", `translate(${margin.left},${margin.top})`);

            const groups = chartData.map(d => d.group);
            const subgroups = ["CR", "PR", "Other"]; // CR, PR, Other (PD for chemo group)
            
            const xScaleGroups = d3.scaleBand()
                .domain(groups)
                .range([0, chartWidth])
                .padding(0.3);

            const yScale = d3.scaleLinear()
                .domain([0, 100]) // Percentage
                .range([chartHeight, 0]);

            const color = d3.scaleOrdinal()
                .domain(subgroups)
                .range(["var(--sobi-teal)", "var(--sobi-yellow)", "var(--sobi-orange)"]); // Teal for CR, Yellow for PR, Orange for Other/PD

            g.append("g")
                .attr("transform", `translate(0,${chartHeight})`)
                .call(d3.axisBottom(xScaleGroups))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px")
                .attr("transform", "translate(0,5)");

            g.append("g")
                .call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px");

            g.append("g")			
                .attr("class", "grid")
                .call(d3.axisLeft(yScale)
                    .ticks(5)
                    .tickSize(-chartWidth)
                    .tickFormat("")
                )
                .selectAll("line")
                .style("stroke", "#e0e0e0")
                .style("stroke-opacity", "0.7");

            // Create a stack generator
            const stack = d3.stack().keys(subgroups);

            // Stack the data
            const stackedData = chartData.map(d => {
                const obj = { group: d.group };
                subgroups.forEach(key => obj[key] = d.values[key] || 0); // Ensure all keys exist
                return obj;
            });
            const series = stack(stackedData);

            // Bars
            g.selectAll(".serie")
                .data(series)
                .enter().append("g")
                  .attr("fill", d => color(d.key))
                .selectAll("rect")
                .data(d => d)
                .enter().append("rect")
                  .attr("x", d => xScaleGroups(d.data.group))
                  .attr("y", d => yScale(d[1]))
                  .attr("height", d => Math.max(0, yScale(d[0]) - yScale(d[1])))
                  .attr("width", xScaleGroups.bandwidth())
                  .attr("rx", 2).attr("ry", 2);
            
            // Add text labels on bars
            series.forEach((serie) => {
                serie.forEach((d) => {
                    const value = d[1] - d[0];
                    if (value > 5) { // Threshold for displaying label
                        g.append("text")
                            .attr("class", "chart-label")
                            .attr("x", xScaleGroups(d.data.group) + xScaleGroups.bandwidth() / 2)
                            .attr("y", yScale(d[0] + value / 2) + 4)
                            .attr("text-anchor", "middle")
                            .style("font-size", "9px")
                            .style("fill", (serie.key === 'CR' && value > 15) ? "white" : "var(--sobi-dark-text)")
                            .text(`${value.toFixed(1)}%`);
                    }
                });
            });
            
            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", margin.top / 2)
                .attr("text-anchor", "middle")
                .style("font-size", "14px")
                .style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)")
                .text(chartTitle);

            const legendData = subgroups.map(key => ({
                label: key === "Other" ? "PD/Other" : key, // Display "PD/Other" for clarity
                color: color(key)
            })).filter(d => chartData.some(group => group.values[d.label.replace("PD/Other", "Other")] > 0 || (d.label === "CR" && group.values["CR"] > 0) || (d.label === "PR" && group.values["PR"] > 0)  ));


            const legendItems = legendContainer.selectAll(".legend-item")
                .data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }
        
        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => {
                    clearTimeout(timeout);
                    func(...args);
                };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawPB3322Chart = debounce(() => drawGroupedBarChartPB3322("#intensiveChemoResponseChart", "#intensiveChemoResponseLegend"), 250);
        
        window.addEventListener('resize', debouncedDrawPB3322Chart);
        
        document.addEventListener('DOMContentLoaded', () => {
            debouncedDrawPB3322Chart();
        });
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawPB3322Chart, 0); 
        }
    </script>
</body>
</html>
